| 764128 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
901 Bacillus Calmette-Guerin can subvert patients antitumor immune response by downregulating HLA-I expression on cancer cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.901 |
Rouanne Mathieu, Adam Julien, Radulescu Camelia, Letourneur Diane, Mouraud Severine, Bredel Delphine, Goubet Anne-Gaelle, Tan Tuan Zea, Bigorgne Amelie, Dussiot Michael, Tselikas Lambros, Susini Sandrine, Danlos François-Xavier, Chabanon Roman, Signolle Nicolas, Schneider Anna, Vacher Sophie, Bieche Ivan, Lebret Thierry, Allory Yves, Soria Jean-Charles, Thiery Jean Paul, Zitvogel Laurence, Marabelle Aurelien |
| 764127 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
897 Infusion episode-related benefits of pembrolizumab Q6W dosing schedule for patients with melanoma treated in the adjuvant and metastatic settings in the United States (US) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.897 |
Aguiar-Ibanez Raquel, Scherrer Emilie, Grebennik Dmitri, Khandelwal Anvi, Cook John, Bagga Shalini, Sawhney Baanie, Soefje Scott |
| 764126 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
889 DuoBody®-CD3x5T4 induces efficient T-cell activation and killing of patient-derived head and neck cancer cells in vitro and ex vivo |
2021-11-01 |
10.1136/jitc-2021-sitc2021.889 |
Ven Rieneke van de, Ganzevles Sonja, Veth Myrthe, Franken Patrick, Breij Esther, Brakenhoff Ruud, Kemper Kristel |
| 764125 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
888 An integrative approach to optimize a synthetic EphA2/CD137 agonist: balancing potency, physiochemical properties, and pharmacokinetics to achieve robust anti-tumor activity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.888 |
Upadhyaya Punit, Mudd Gemma, Hurov Kristen, Lahdenranta Johanna, Repash Elizabeth, Kristensson Julia, McDonnell Kevin, Brandish Philip, Jeffrey Phil, Keen Nicholas |
| 764124 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
887 Repolarization of T cells by AMV564 in patients progressing on checkpoint blockade |
2021-11-01 |
10.1136/jitc-2021-sitc2021.887 |
Smith Victoria, Eckard Sterling, Rojo Bianca, Chun Patrick |
| 764123 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
886 Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures |
2021-11-01 |
10.1136/jitc-2021-sitc2021.886 |
Sazinsky Steve, Nguyen Phuong, Zafari Mohammad, Phennicie Ryan, Wahle Joe, Komoroski Veronica, Rooney Kathryn, Mizzoni Craig, Klebanov Boris, Manfra Denise, Ritter Jessica, Feldman Igor, Novobrantseva Tatiana |
| 764122 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
882 Selective affinity-enhanced T cell receptor bispecific targeting of KRAS G12D neoantigen driven cancers |
2021-11-01 |
10.1136/jitc-2021-sitc2021.882 |
Whale Andrew, Poole Andrew, Karuppiah Vijaykumar, Hartt Annabelle, Haidar Jaafar, Moureau Sylvie, Lin Aimee Bence, Kamp Marc Van der, Plowman Gregory, Vuidepot Annelise, Cole David, Chillakuri Chandramouli |
| 764121 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
880 Tetravalent, bispecific innate cell engager AFM24 enhances macrophage mediated tumor cell phagocytosis |
2021-11-01 |
10.1136/jitc-2021-sitc2021.880 |
Pinto Sheena, Wingert Susanne, Pahl Jens, Beez Armin, Purr Sabrina, Reusch Uwe, Schottelius Arndt, Koch Joachim |
| 764120 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
692 Tim-3 expression drives phenotypic and functional changes in Treg in secondary lymphoid organs and the tumor microenvironment, effecting tumor burden |
2021-11-01 |
10.1136/jitc-2021-sitc2021.692 |
Banerjee Hridesh, Nieves-Rosado Hector, Murter Benjamin, Kane Lawrence |
| 764119 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
691 Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.691 |
Bonaventura Paola, Alcazer Vincent, Mutez Virginie, Tonon Laurie, Martin Juliette, Chuvin Nicolas, Boulos Rasha, Estornes Yann, Valladeau-Guilemond Jenny, Viari Alain, Caux Christophe, Depil Stephane |
